IDP Pharma has spun out a product with cosmetic applications. The new company is backup by IDP’s investors, is fully financed and will be responsible for the formulation and clinical development of IDP-312.

This early stage product was developed thanks to IDP Platform, a unique technology that allows to design for the first time drugs for targeting intrinsically disordered transcription factors.

IDP Pharma and BCN Peptides has entered a collaboration for the development of peptidomimetics. IDP Pharma will use its technology, IDP-Platform , to design peptidomimetics with target-specificity, intrinsic cell permeability properties and enhanced stability to target intra cellular proteins. BCN Peptide will optimize the synthesis and scale up the lead compounds.